Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 120

1.

Use of MenACWY-CRM in adolescents in the United States.

Black S, Block SL.

J Adolesc Health. 2013 Mar;52(3):271-7. doi: 10.1016/j.jadohealth.2012.07.017. Epub 2012 Sep 25. Review.

PMID:
23299001
[PubMed - indexed for MEDLINE]
2.

Meningococcal quadrivalent (serogroups A, C, w135, and y) conjugate vaccine (Menveo): in adolescents and adults.

Deeks ED.

BioDrugs. 2010 Oct 1;24(5):287-97. doi: 10.2165/11204790-000000000-00000. Review.

PMID:
20795751
[PubMed - indexed for MEDLINE]
3.

Prevention and control of meningococcal disease: recommendations of the Advisory Committee on Immunization Practices (ACIP).

Cohn AC, MacNeil JR, Clark TA, Ortega-Sanchez IR, Briere EZ, Meissner HC, Baker CJ, Messonnier NE; Centers for Disease Control and Prevention (CDC).

MMWR Recomm Rep. 2013 Mar 22;62(RR-2):1-28.

PMID:
23515099
[PubMed - indexed for MEDLINE]
Free Article
4.

Phase III comparison of an investigational quadrivalent meningococcal conjugate vaccine with the licensed meningococcal ACWY conjugate vaccine in adolescents.

Jackson LA, Baxter R, Reisinger K, Karsten A, Shah J, Bedell L, Dull PM; V59P13 Study Group.

Clin Infect Dis. 2009 Jul 1;49(1):e1-10. doi: 10.1086/599117.

PMID:
19476428
[PubMed - indexed for MEDLINE]
Free Article
5.

Antibody persistence and booster response of a quadrivalent meningococcal conjugate vaccine in adolescents.

Baxter R, Reisinger K, Block SL, Izu A, Odrljin T, Dull P.

J Pediatr. 2014 Jun;164(6):1409-15.e4. doi: 10.1016/j.jpeds.2014.02.025. Epub 2014 Mar 20.

PMID:
24657122
[PubMed - indexed for MEDLINE]
6.

Menveo®): a novel quadrivalent meningococcal CRM197 conjugate vaccine against serogroups A, C, W-135 and Y.

Cooper B, DeTora L, Stoddard J.

Expert Rev Vaccines. 2011 Jan;10(1):21-33. doi: 10.1586/erv.10.147. Review.

PMID:
21162617
[PubMed - indexed for MEDLINE]
7.

Quadrivalent meningococcal vaccination of adults: phase III comparison of an investigational conjugate vaccine, MenACWY-CRM, with the licensed vaccine, Menactra.

Reisinger KS, Baxter R, Block SL, Shah J, Bedell L, Dull PM.

Clin Vaccine Immunol. 2009 Dec;16(12):1810-5. doi: 10.1128/CVI.00207-09. Epub 2009 Oct 7.

PMID:
19812260
[PubMed - indexed for MEDLINE]
Free PMC Article
8.

Safety of a quadrivalent meningococcal serogroups A, C, W and Y conjugate vaccine (MenACWY-CRM) administered with routine infant vaccinations: results of an open-label, randomized, phase 3b controlled study in healthy infants.

Abdelnour A, Silas PE, Lamas MR, Aragón CF, Chiu NC, Chiu CH, Acuña TH, Castrejón Tde L, Izu A, Odrljin T, Smolenov I, Hohenboken M, Dull PM.

Vaccine. 2014 Feb 12;32(8):965-72. doi: 10.1016/j.vaccine.2013.12.034. Epub 2014 Jan 4.

PMID:
24397906
[PubMed - indexed for MEDLINE]
9.

A randomized trial to determine the tolerability and immunogenicity of a quadrivalent meningococcal glycoconjugate vaccine in healthy adolescents.

Jackson LA, Jacobson RM, Reisinger KS, Anemona A, Danzig LE, Dull PM.

Pediatr Infect Dis J. 2009 Feb;28(2):86-91. doi: 10.1097/INF.0b013e31818a0237.

PMID:
19116603
[PubMed - indexed for MEDLINE]
10.

Immunogenicity and immune memory of a nonadjuvanted quadrivalent meningococcal glycoconjugate vaccine in infants.

Perrett KP, Snape MD, Ford KJ, John TM, Yu LM, Langley JM, McNeil S, Dull PM, Ceddia F, Anemona A, Halperin SA, Dobson S, Pollard AJ.

Pediatr Infect Dis J. 2009 Mar;28(3):186-93. doi: 10.1097/INF.0b013e31818e037d.

PMID:
19209097
[PubMed - indexed for MEDLINE]
11.
12.
13.

Immunogenicity and safety of a quadrivalent meningococcal serogroups A, C, W-135 and Y tetanus toxoid conjugate vaccine (MenACWY-TT) administered to adults aged 56 Years and older: results of an open-label, randomized, controlled trial.

Dbaibo G, El-Ayoubi N, Ghanem S, Hajar F, Bianco V, Miller JM, Mesaros N.

Drugs Aging. 2013 May;30(5):309-19. doi: 10.1007/s40266-013-0065-0.

PMID:
23494214
[PubMed - indexed for MEDLINE]
Free PMC Article
14.

Safety and immunogenicity of one dose of MenACWY-CRM, an investigational quadrivalent meningococcal glycoconjugate vaccine, when administered to adolescents concomitantly or sequentially with Tdap and HPV vaccines.

Arguedas A, Soley C, Loaiza C, Rincon G, Guevara S, Perez A, Porras W, Alvarado O, Aguilar L, Abdelnour A, Grunwald U, Bedell L, Anemona A, Dull PM.

Vaccine. 2010 Apr 19;28(18):3171-9. doi: 10.1016/j.vaccine.2010.02.045. Epub 2010 Feb 26.

PMID:
20189491
[PubMed - indexed for MEDLINE]
15.

Immunogenicity and safety of a meningococcal serogroup A, C, Y and W glycoconjugate vaccine, ACWY-TT.

Findlow H, Borrow R.

Adv Ther. 2013 May;30(5):431-58. doi: 10.1007/s12325-013-0032-5. Epub 2013 May 28. Review.

PMID:
23712402
[PubMed - indexed for MEDLINE]
16.

Licensure of a meningococcal conjugate vaccine (Menveo) and guidance for use - Advisory Committee on Immunization Practices (ACIP), 2010.

Centers for Disease Control and Prevention (CDC).

MMWR Morb Mortal Wkly Rep. 2010 Mar 12;59(9):273.

PMID:
20224545
[PubMed - indexed for MEDLINE]
Free Article
17.

Immunogenicity and safety of the quadrivalent meningococcal serogroups A, C, W-135 and Y tetanus toxoid conjugate vaccine (MenACWY-TT) in 2-10-year-old children: results of an open, randomised, controlled study.

Knuf M, Romain O, Kindler K, Walther U, Tran PM, Pankow-Culot H, Fischbach T, Kieninger-Baum D, Bianco V, Baine Y, Miller J.

Eur J Pediatr. 2013 May;172(5):601-12. doi: 10.1007/s00431-012-1924-0. Epub 2013 Jan 11.

PMID:
23307281
[PubMed - indexed for MEDLINE]
Free PMC Article
18.

Novel quadrivalent meningococcal A, C, W-135 and Y glycoconjugate vaccine for the broader protection of adolescents and adults.

Pace D.

Future Microbiol. 2010 Nov;5(11):1629-40. doi: 10.2217/fmb.10.137.

PMID:
21133685
[PubMed - indexed for MEDLINE]
19.

Meningococcal quadrivalent (serogroups A, C, W135 and Y) tetanus toxoid conjugate vaccine (Nimenrix™).

Croxtall JD, Dhillon S.

Drugs. 2012 Dec 24;72(18):2407-30. doi: 10.2165/11209580-000000000-00000. Review.

PMID:
23231026
[PubMed - indexed for MEDLINE]
20.

MenACWY-TT vaccine for active immunization against invasive meningococcal disease.

Papaevangelou V, Spyridis N.

Expert Rev Vaccines. 2012 May;11(5):523-37. doi: 10.1586/erv.12.32. Review.

PMID:
22827239
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk